Author: Bellanti, Francesco; Vendemiale, Gianluigi
Title: Coronavirus disease 2019 and non-alcoholic fatty liver disease Cord-id: owqn00rs Document date: 2021_9_27
ID: owqn00rs
Snippet: The coronavirus disease 2019 (COVID-19) pandemic may present with a broad range of clinical manifestations, from no or mild symptoms to severe disease. Patients with specific pre-existing comorbidities, such as obesity and type 2 diabetes, are at high risk of coming out with a critical form of COVID-19. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and, because of its frequent association with metabolic alterations including obesity and type 2 diabetes, it h
Document: The coronavirus disease 2019 (COVID-19) pandemic may present with a broad range of clinical manifestations, from no or mild symptoms to severe disease. Patients with specific pre-existing comorbidities, such as obesity and type 2 diabetes, are at high risk of coming out with a critical form of COVID-19. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and, because of its frequent association with metabolic alterations including obesity and type 2 diabetes, it has recently been re-named as metabolic-associated fatty liver disease (MAFLD). Several studies and systematic reviews pointed out the increased risk of severe COVID-19 in NAFLD/MAFLD patients. Even though dedicated mechanistic studies are missing, this higher probability may be justified by systemic low-grade chronic inflammation associated with immune dysregulation in NAFLD/MAFLD, which could trigger cytokine storm and hypercoagulable state after severe acute respiratory syndrome coronavirus 2 infection. This review focuses on the predisposing role of NAFLD/MAFLD in favoring severe COVID-19, discussing the available information on specific risk factors, clinical features, outcomes, and pathogenetic mechanisms.
Search related documents:
Co phrase search for related documents- acute phase and adaptive innate immune response: 1
- acute phase and adipose tissue: 1
- acute phase and liver biopsy: 1, 2
- acute phase and liver damage: 1, 2, 3, 4, 5, 6
- acute phase and liver disease: 1, 2, 3, 4, 5, 6
- acute phase and liver fibrosis: 1
- acute phase and liver immunity: 1
- acute phase and liver kupffer cell: 1
- acute phase and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory failure and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory failure and adaptive innate immune response: 1
- acute respiratory failure and liver biopsy: 1
- acute respiratory failure and liver damage: 1, 2, 3, 4, 5
- acute respiratory failure and liver disease: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory failure and liver fibrosis: 1
- acute respiratory failure and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- adaptive innate and liver immunity: 1, 2
- adaptive innate and liver parenchyma: 1
- adaptive innate and long covid: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date